US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Nutriband Inc. - Warrant (NQ:NTRBW)

0.5500 UNCHANGED
Delayed Quote Updated: 3:59 PM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nutriband Inc. - Warrant

< Previous 1 2 3 4 5 6 Next >
News headline image
Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology
Via ACCESSWIRE
News headline image
Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch
Via ACCESSWIRE
News headline image
Nutriband Inc. Authorizes $1M Share Buyback Program
Via ACCESSWIRE
News headline image
Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
Via ACCESSWIRE
News headline image
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25
Via ACCESSWIRE
News headline image
Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology
Via ACCESSWIRE
News headline image
Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors
Via ACCESSWIRE
News headline image
Nutriband Inc. Announces $8.4M Private Placement
Via ACCESSWIRE
News headline image
Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st
Via ACCESSWIRE
News headline image
Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl
Via ACCESSWIRE
News headline image
Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year
Via ACCESSWIRE
News headline image
Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission
Via ACCESSWIRE
News headline image
Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group
Via ACCESSWIRE
News headline image
Nutriband Inc. Begins Manufacturing for Major Sports Brand Licensee Fit for Life Group, Whose Collection of Partnered Brands Include Reebok, Adidas and New Balance
Via ACCESSWIRE
News headline image
Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology
Via ACCESSWIRE
News headline image
Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023
Via ACCESSWIRE
News headline image
Nutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch
Via ACCESSWIRE
News headline image
Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting
Via ACCESSWIRE
News headline image
Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting
Via ACCESSWIRE
News headline image
Nutriband CEO Publishes Letter to Shareholders
Via ACCESSWIRE
News headline image
Nutriband Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch
Via ACCESSWIRE
News headline image
Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling
Via ACCESSWIRE
News headline image
Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape
Via ACCESSWIRE
News headline image
Nutriband’s Aversa(TM) Buprenoprhine May Reach Peak Annual Sales 0f $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm
Via ACCESSWIRE
Nutriband’s Innovative Patent Breaks New Ground in Transdermal Medications
Via Get News
Topics Intellectual Property
Nutriband Unveils Groundbreaking Innovation in Transdermal Medications
ORLANDO, FL / September 20, 2023 (PlatoData via 500NewsWire) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a leading developer of transdermal pharmaceutical products, proudly announces the issuance... 
Via TheNewswire.com
Topics Intellectual Property
Nutriband Unveils Groundbreaking Innovation in Transdermal Medications
--News Direct-- 
Via News Direct
Topics Intellectual Property
News headline image
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death Intellectual Property
Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology
Patent issuance expands U.S. patent portfolio for AVERSA™ transdermal abuse deterrent technology Orlando, FL – September 20, 2023 – Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of... 
Via FinancialNewsMedia
Topics Intellectual Property
News headline image
Nutriband Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 Next >